Latest Clinical & Research News
Specialty: Oncology
A growing set of low-risk cancers, including early-stage thyroid and kidney cancers, is associated with excellent outcomes regardless of management strategy. Given the risks associated with overtreatment of these cancers, it follows that many patients should be treated nonoperatively. Read More
The Society of Surgical Oncology (SSO) is holding its annual International Conference on Surgical Cancer Care in Boston on March 22-25.
Several leaders in surgical oncology from Brigham and Women’s Hospital/Dana-Farber Brigham Cancer Center will present their latest research and clinical advancements in breast cancer, colorectal cancer, melanoma, sarcoma, and more. Read More
A recently approved and widely adopted imaging study that improves detection of prostate cancer recurrence in patients who have undergone radical prostatectomy is having an unintended effect of delaying potentially life-saving salvage treatment with radiation and androgen deprivation therapy, according to a study led by Anthony Victor D’Amico, MD, PhD, chief of Genitourinary Radiation Oncology, Dana-Farber Brigham Cancer Center.
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve clinical outcomes and prognosis in patients with peritoneal metastasis. However, it is associated with a significant complication rate and a long postsurgical recovery in the hospital.
Read More
With about 12,000 to 13,000 cases diagnosed in the United States each year, sarcomas are among medicine’s rarest cancers. Since many oncologists may only see one or two cases during their career, patients often struggle to find experienced providers. Read More
Investigators at Dana-Farber Brigham Cancer Center have uncovered a potentially serious flaw in the current standard of care for patients with positive pelvic node prostate cancer (pN1 PC). They found that adjuvant radiation therapy (aRT) is associated with a decreased risk of death compared with early salvage radiation therapy (sRT) in men with four or more positive lymph nodes. Moreover, the reduction increases by 8% for each additional positive pelvic lymph node found at surgery. Read More
Dana-Farber Brigham Cancer Center is world-renowned for its commitment to cutting-edge research. Over the years, its researchers have turned scientific discoveries into life-saving treatments, contributing to the development of 35 of 75 cancer drugs recently approved by the FDA for use in cancer patients. Read More
Over the last few decades, Dana-Farber Brigham Cancer Center has advanced the care and management of head and neck cancer patients through a collaborative, multidisciplinary approach. The team has focused on surgical innovations such as free flap reconstruction and minimally-invasive transoral robotic surgery to help patients recover their speech and swallowing functions while delivering highly effective and state-of-the-art therapeutic interventions. Advances in chemotherapy, immunotherapy, and radiation delivery techniques have clearly helped to improve patient outcomes. Read More
Joshua D. Bernstock, MD, PhD, in the Department of Neurosurgery at Brigham and Women’s Hospital, Gregory K. Friedman, MD, of the University of Alabama at Birmingham, and colleagues reviewed novel therapies that target oncometabolism and tumor immunometabolism.
Read More...
Researchers at Brigham and Women’s Hospital have designed a biologic agent, dubbed EnMSCBif, to bind to death receptor 5 (DR5) on the surface of glioblastoma cells and trigger extrinsic programmed cell death. They report on the high potential of EnMSCBif to be translated into clinical use.
Read More...